Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
about
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndromeManagement of Membranous Nephropathy in Western CountriesLow-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathyRituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients.Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.Pharmacological treatment of primary membranous nephropathy in 2016.Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients.Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trialImmunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trialsStepwise treatment using corticosteroids alone and in combination with cyclosporine in korean patients with idiopathic membranous nephropathyLong-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategyPrimary Membranous Nephropathy.Increasing frequency of idiopathic membranous nephropathy in primary glomerular disease: a 10-year renal biopsy study from a single Chinese nephrology centre.Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy.Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy.
P2860
Q24193098-57C8CEF4-0823-43CE-9E66-F51399189EE4Q26740477-6D3CD2AA-0EEE-467D-8F1E-5F566639D61FQ35664611-87C5B07E-F4AE-42BB-9783-7BB112341935Q35791799-D23DF497-8C4D-48FD-821B-E280231B30EBQ35840057-D5B1B404-BFC5-4C10-9AF3-C677F637988FQ36088887-CB7A9F39-246F-46B5-A9B4-C71CA25C7612Q36106413-DC06E0D6-D256-4C7A-BF7E-88890AA30074Q36240947-5235D15D-2EAC-4C43-B207-5BAFBFF2FE14Q36662933-F8B6FAE2-E1F3-44BB-A02E-7EA65B22118DQ36810470-5029F12D-F87A-44A0-B368-06F30E352D4FQ36872799-7D06CEAB-0D6E-4F89-B2D3-1547D1210CFCQ37411651-4E64F4A4-633B-4EA4-9F8A-027774D186ECQ38760741-0BBCB64E-2370-4DA2-8B87-08E96FC3E6C9Q41659949-8CB69BAB-DEEC-4472-B8BA-D05829B50AAAQ42155627-90C8931B-E249-4109-8EB9-B7C6DFF6290EQ42639047-3AA1185A-9EB8-4FF8-9D04-BD4655254E14
P2860
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
@en
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
@nl
type
label
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
@en
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
@nl
prefLabel
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
@en
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
@nl
P356
P1476
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt.
@en
P2093
Jack F M Wetzels
Julia M Hofstra
P304
P356
10.1093/NDT/GFQ017
P407
P577
2010-02-03T00:00:00Z